We investigated the prevalence of anaemia (haemoglobin concentration < 12 g/dl) in 336 women with early-stage breast cancer and its association with other known prognostic factors. The median followup period was 60.5 months (range 9 -123 months). Seventy-nine women (23.5%) had a low pre-treatment haemoglobin concentration, but anaemia was not correlated with age, tumour size, nodal status, histological grade or hormone receptor status. Univariate analysis revealed that disease-free survival and overall survival were shorter in patients with anaemia at the time of diagnosis than in patients with normal haemoglobin concentrations. Anaemia remained a significant prognostic factor for disease-free survival and overall survival in the multivariate analysis (relative risk, 1.884 and 1.785,  respectively) . These results suggest that pre-treatment haemoglobin concentration is an independent prognostic factor in patients with early-stage breast cancer.
Introduction
Anaemia occurs in over 50% of patients with cancer, and is the most common and persistent haematological complication of cancer. 1 Anaemia is defined as an inadequate circulating concentration of haemoglobin or red blood cells.
The frequency of anaemia in patients with cancer varies according to tumour type and treatment. Over half of patients with lung tumours, lymphoma, gynaecological or genitourinary tumours may develop severe anaemia requiring blood transfusion. 2 Several factors can cause anaemia in these patients, including the underlying disease, chemotherapy or radiation therapy. 1 -4 Anaemia is a well-recognized complication of cancer and cancer treatment, but little information is available about its prognostic and predictive values relating to treatment. The majority of studies demonstrate that anaemia is an independent adverse prognostic and predictive factor for outcome, although some studies suggest it has little or no prognostic value. Several recent prospective and retrospective studies, as well as data from pre-clinical studies, support the conclusion that haemoglobin concentration may influence treatment outcome parameters, however. 5 -8 Data concerning the impact of anaemia on prognosis in patients with early-stage breast cancer (BC) are very limited. In this retrospective study we aimed, therefore, to investigate the prognostic value of pretreatment haemoglobin concentration in women with early BC.
Patients and methods

PATIENT DATA
This was a retrospective study, so patient data were obtained from medical records at the GATA Haydarpasa Training Hospital. Between December 1993 and April 2003, only women at least 18 years of age who had undergone a modified radical mastectomy with axillary lymph node dissection for invasive ductal carcinoma 5 cm or less in diameter (pathological stage T1 or T2) were included. Patients were excluded for the following reasons: a history of cancer (other than treated non-melanoma skin cancer or carcinoma in situ of the cervix); bilateral BC or multifocal primary breast tumours; concurrent illness that would preclude the adjuvant therapy; and lack of availability for follow-up.
All patients had been followed up every 3 -6 months for a period of 5 years after completing local therapy and systemic adjuvant treatment; this is in accordance with standard follow-up procedures. After 5 years, the patients were seen on a yearly basis. If signs or symptoms suggestive of a possible relapse were observed, additional assessments (bone scintigraphy, ultrasonography or computed tomography scans of the abdomen and chest, and so on, as clinically indicated) were performed.
The pre-treatment (baseline) clinicopathological variables noted from the patient records were: age; tumour size; number of positive lymph nodes; histological grade; oestrogen receptor status; and progesterone receptor status. The types and combinations of therapy received were also noted.
Anaemia was defined as a haemoglobin concentration < 12 g/dl. The women were divided into two groups based on this definition and their pre-treatment haemoglobin concentration: < 12 g/dl, anaemic patients; and ≥ 12 g/dl, non-anaemic patients. Disease-free survival was taken as the time from the date of diagnosis to the date of first relapse at any site, or to the appearance of a second primary BC. Overall survival was measured from the date of diagnosis to death from any cause or to last follow-up visit. As this was a retrospective study, patient consent and ethical approval were not needed.
STATISTICAL ANALYSIS
Baseline differences in clinicopathological variables between anaemic and nonanaemic patients were assessed using the χ 2 test or Fisher's exact test. Spearman's rank correlation was used to test any associations between haemoglobin concentration and other variables.
Survival probabilities were analysed using the methods of Kaplan and Meier. The log rank test was used to compare survival curves with respect to all measured variables. The Cox proportional hazards regression model was used to assess the significance of potential prognostic factors as predictive parameters for patient survival. A P-value < 0.05 was considered to be statistically significant.
Results
The records of 336 women with early-stage BC were analysed for the study. The median age of the patients was 53.5 years (range, 28 -78 years). Overall, 28.6% of patients received locoregional radiotherapy, 60.8% received adjuvant chemotherapy, and 64.6% with a positive hormone receptor status received hormonal therapy (tamoxifen). The median follow-up period was 60.5 months (range, 9 -123 months); 79 patients (23.5%) had anaemia. The pre-treatment patient characteristics are shown in Table 1 .
There were no significant differences in baseline clinicopathological variables between the patients with and without anaemia ( Table 2) .
Associations between the presence or absence of anaemia and clinicopathological
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Prognostic factors in early breast cancer factors are shown in Table 3 . There was no significant association between haemoglobin concentration and any of the factors, or any correlations identified with adjuvant therapy. 
Prognostic factors in early breast cancer
There was also a significant difference in overall survival between two haemoglobin concentration groups (P = 0.039, log rank test; Fig. 2 ). In patients with anaemia, cumulative survival was 50.8%, while patients without anaemia had longer overall survival (cumulative survival: 56.7%).
PROGNOSTIC ANALYSIS OF DISEASE-FREE SURVIVAL
In the univariate analysis, pre-treatment haemoglobin concentration, tumour size, number of positive lymph nodes, histological grade, and oestrogen and progesterone receptor expression were strong predictors of disease-free survival. There was no significant relationship between disease-free survival and age (Table 4 ).
Multivariate analysis showed that reduced disease-free survival was associated with low haemoglobin concentration, larger tumour size, higher number of positive lymph nodes, higher histological grade tumour, and negative hormone receptor status (Table 4 ).
PROGNOSTIC ANALYSIS OF OVERALL SURVIVAL
Univariate analysis demonstrated significant associations between overall survival and haemoglobin concentration, tumour size, number of positive lymph nodes, histological grade and hormone receptor expression. There was no significant relationship between age and overall survival ( Table 5 ).
In the multivariate analysis, patients with low haemoglobin concentrations, larger tumour sizes, positive lymph node status, higher histological grade tumours or negative hormone receptor expression had a significantly reduced overall survival ( Table 5 ).
Discussion
The incidence and severity of anaemia depends on many factors, including the nutritional status of the patient, type of cancer, and stage and extent of disease. A high incidence of anaemia (50 -60%) occurs in patients with lymphomas, multiple myeloma, lung tumours, and gynaecological or genitourinary tumours, 2 although the occurrence of anaemia in patients with solid tumours is less frequent than that observed for haematological malignancies. 2 In a retrospective study of 310 patients with stage II and III BC, Kirshner et al. 9 observed anaemia in a significant proportion (31%) of patients. In another study, 7.1% (21/294) of patients had haemoglobin concentrations < 12 g/dl at diagnosis. 10 In our study, 23.5% of the patients had anaemia.
Evidence accumulated over the past 10 years suggests that anaemia is correlated with poor clinical outcome in patients with cancer. 5 -10 Hypoxia within the tumour mass is a common occurrence in a variety of solid tumours, and some evidence suggests that tumour hypoxia contributes to the malignancy of the disease. It is, therefore, considered to be an independent marker for poor prognosis. 11 -16 The most extensive pool of results on the effect of anaemia on treatment and clinical 
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outcomes is from studies of patients with head and neck cancer. 5, 6 Data for BC are very limited. 10, 17 In one retrospective study of 290 patients with early BC, the haemoglobin concentration significantly correlated with disease-free survival for patients receiving breast-conserving surgery followed by adjuvant radiotherapy (relative risk: 0.67 per g/dl; P = 0.007); this correlation was independent of other standard BC risk factors. 10 There was no correlation in patients who underwent a mastectomy, however. We divided our patients into two groups, according to their pre-treatment haemoglobin concentration. To exclude selection bias, we tested baseline differences in clinicopathological variables between these two patient groups, and did not find any significant differences. Univariate analysis revealed that disease-free and overall survival were shorter in patients with anaemia at the time of diagnosis than in patients with normal haemoglobin concentrations. Anaemia remained a significant prognostic factor for both disease-free and overall survival following multivariate analysis. In multivariate analysis, anaemia is much more significant for disease-free survival than for overall survival. This might be due to other known prognostic factors for metastatic BC, including the site or number of distant metastases, the presence of visceral metastases, and so on. We also performed a Spearman correlation analysis to determine the clinicopathological factors associated with anaemia, which showed that anaemia did not correlate with other prognostic factors. This result suggests that our significant observations are not based on a correlation between known prognostic indicators.
There are a number of possible mechanisms by which a low haemoglobin concentration may impair survival. 18 Anaemia can reduce the oxygen capacity of the blood, further contributing to the development of hypoxia. In a study performed by Vaupel et al., 19 the association between blood haemoglobin concentration and BC oxygenation was examined. They found that in BC patients, the median haemoglobin concentration correlated positively with the median partial oxygen (pO 2 ) value. In contrast, in normal tissues, median pO 2 values remained constant irrespective of the haemoglobin concentration. The authors also reported that with BC, even mild anaemia was a major cause for developing hypoxia or anoxia. 19 The effect of oxygenation on tumour biology has been investigated for several decades. Some evidence suggests that hypoxia within the tumour micro-environment may lead to growth stasis or impairment through necrosis or proteome changes of the neoplastic and stroma cells, resulting in cellular quiescence, differentiation and apoptosis. 12, 13 Hypoxia has been shown to increase genomic instability, leading to more genetic variation via mutations. Such mutations could increase treatment resistance and metastatic potential, and decrease cellular response to apoptosis signals. 20 -22 Moreover, hypoxia may induce changes in the expression of oxygen-dependent proteins, such as vascular endothelial growth factor (VEGF), within the tumour cells. These proteins stimulate angiogenesis; therefore, altering their expression could result in a higher proliferation rate of tumour cells. 23 -27 In a cell culture experiment, the expression of VEGF was up-regulated in response to hypoxia, 23 and Dunst et al. 28 also showed that a low haemoglobin concentration is associated with increased serum VEGF concentrations in cancer patients.
Hypoxia can also enhance the ability of cells to invade the extracellular matrix and undergo metastasis 12,27 -31 by upregulating
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Prognostic factors in early breast cancer enzymes and other proteins involved in tumour invasiveness (e.g. urokinase-type plasminogen activator). Graham et al. 27 found that urokinase-type plasminogen activator receptor expression increased in response to hypoxic conditions. In the same study, invasiveness of carcinoma cells was significantly higher under hypoxic compared with normal conditions. Tumour-cell detachment is facilitated by hypoxia as it reduces expression of surface adhesion molecules, such as CD44 and N-CAM, and adhesion to extracellular matrices without loss of cell viability. 31 At the same time, hypoxia-induced downregulation of cell-surface integrins has been observed along with the associated reduction in cellular adhesion. 31 A different postulated explanation for the adverse impact of tumour hypoxia on survival involves ionizing radiation and free radicals. Ionizing radiation leads to the formation of free radicals within cells. In the presence of oxygen, the free radicals are fixed and interact with DNA and cell membranes to cause cell death. In hypoxic conditions, however, free radicals are not fixed, so cell death may not occur. 32 Laboratory data indicate that red blood cells, in addition to transporting oxygen, may also play a role in the transport of chemotherapeutic agents to tumour cells. In the presence of anaemia, decreased amount of chemotherapeutic agents delivered to tumour cells might reduce the effectiveness of chemotherapy. 33 Our study shows an association between anaemia with decreased survival in patients with early stage BC. It is difficult to determine the precise reason for this association, but it is apparent that a complex relationship exists among hypoxia, the result of anaemia, and treatment or clinical outcomes. The impact of anaemia on outcome may be related to the degree of tumour oxygenation, but tumour hypoxia is a multifactorial process. Anaemia could be the underlying cause of tumour hypoxia, or merely a marker of poorer outcome. Other factors related to anaemia may also affect outcome. Accumulating evidence demonstrates the prognostic value of haemoglobin concentration, while the effect of red blood cells on the biological, mechanistic response to cancer remains elusive.
